Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03014648 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Liza Villaruz, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03014648 is a Phase 2 study that has completed, run by Liza Villaruz, MD. The registered enrollment target is 28 participants.
The verdict
NCT03014648, a Phase 2 study, has completed, sponsored by Liza Villaruz, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1 therapy with either nivolumab or pembrolizumab. In order to account for the variability of response kinetics to PD-1 directed therapy, patients will be enrolled in 3 parallel cohorts based on the best overall response to PD-1 directed therapy. * Cohort 1 (progressive disease) * Cohort 2 (stable disease with minimum 12 weeks of therapy) * Cohort 3 (partial to complete response followed by progressive disease)
Interventions
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03014648
The ClinicalTrials.gov registry entry for NCT03014648 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liza Villaruz, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab is the first listed.
NCT03014648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03014648 about?
NCT03014648 is a clinical study titled "Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)". This is a phase II clinical trial aimed at evaluating the efficacy of PD-L1 inhibition with atezolizumab in advanced squamous and non-squamous NSCLC patients previously treated with anti-PD-1 therapy with either nivolumab or pembrolizumab. In order to account for the variability of response kinetic...
What is the current status of trial NCT03014648?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2017-07-18. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT03014648?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03014648?
This trial is sponsored by Liza Villaruz, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.